Very early molecular responses in the first two months of therapy are highly predictive of deep molecular responses at 18 months, in chronic myeloid leukemia patients treated upfront with nilotinib
Servizos
Servizos
Data de publicación
2014Título da revista
Haematologica
Tipo de contido
Publicación de congreso
